Novel intrasaccular aneurysm treatment device receives FDA PMA approval
The WEB® Aneurysm Embolization System is the first intrasaccular flow disruptor PMA approved for the embolization of wide neck bifurcation aneurysmsAliso Viejo, CA. – January 7, 2019 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System is the first and only PMA approved device in the new category of intrasaccular flow disruptors for aneurysm embolization. (The WEB System was developed by Sequent Medical, Inc. and Sequent was acquired by Terumo in 2016).